Nicole Gebran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Gebran has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abdel Rahman Elrashedy
Johnson and Johnson Middle East FZ-LLC, Dubai Healthcare City, Dubai, United Arab Emirates
1 shared publication - Abdulrazaq S. Al-Jazairi
King Faisal Specialist Hospital and Research Center
1 shared publication Amr Nasrallah
Johnson and Johnson Middle East FZ-LLC, Dubai Healthcare City, Dubai, United Arab Emirates
1 shared publication- Lamia AlHajri
Higher Colleges of Technology
1 shared publication - Lorenzo Pradelli
AdRes HE&OR, Turin, Italy
1 shared publication - Mehnaz Zafar Ali
Al Amal Psychiatric Hospital
1 shared publication
Latest Publications
- Open Access
- 12 July 2026
- Published by Springer Nature
- p. 481-504
Pharmacoeconomics of Rheumatic Diseases in the Arab World
Pharmacologic therapy constitutes an integral part of managing rheumatologic diseases, with a diversity of available options from simple molecules to complex biologics and a trending rise in the cost of therapy accompanying novel innovations. The application of pharmacoeconomic principles is thus of particular significance regarding drug therapy selection in rheumatology. Additionally, there is current global interest in adopting new health technology assessment models and value-based approaches to care delivery. The Arab world is no different, with potential country-specific roadmaps in draft or the initial phases of implementation involving key stakeholders from regulators, payers, manufacturers, health economists, and healthcare providers. This chapter will define basic concepts in health economics, shed light on rheumatologic disease burden and budget impact, and explore approaches to cost-effective therapies. We conclude with recommendations to support the adoption of biosimilars as cost-effective treatment alternatives, highlight barriers to their adoption, and suggest means to strengthen pharmacovigilance as the way forward.
- 12 July 2026
- Published by Springer Nature
- p. 481-504
Open AccessPharmacoeconomics of Rheumatic Diseases in the Arab World
Pharmacologic therapy constitutes an integral part of managing rheumatologic diseases, with a diversity of available options from simple molecules to complex biologics and a trending rise in the cost of therapy accompanying novel innovations. The application of pharmacoeconomic principles is thus of particular significance regarding drug therapy selection in rheumatology. Additionally, there is current global interest in adopting new health technology assessment models and value-based approaches to care delivery. The Arab world is no different, with potential country-specific roadmaps in draft or the initial phases of implementation involving key stakeholders from regulators, payers, manufacturers, health economists, and healthcare providers. This chapter will define basic concepts in health economics, shed light on rheumatologic disease burden and budget impact, and explore approaches to cost-effective therapies. We conclude with recommendations to support the adoption of biosimilars as cost-effective treatment alternatives, highlight barriers to their adoption, and suggest means to strengthen pharmacovigilance as the way forward.
- Open Access
- 2 March 2026
- Published by Seed SRL in Farmeconomia. Health economics and therapeutic pathways
- Vol. 27 (1) , 45-54
Clinical and Economic Benefits of Long-Acting Injectable Paliperidone in Schizophrenia: A UAE-Based Modeling Study
INTRODUCTION: Poor adherence to oral antipsychotic (OAP) therapy is a major driver of relapse in patients with schizophrenia, as only 50% or fewer patients are adherent to OAP during the first year, leading to suboptimal clinical outcomes and substantial healthcare costs. Long-acting injectable (LAI) antipsychotics enhance treatment continuity and sustained drug exposure, with real-world data showing improved effectiveness as dosing intervals lengthen due to better adherence. We evaluate the clinical and economic consequences, in the United Arab Emirates (UAE) healthcare setting, of switching patients with schizophrenia from OAPs to paliperidone LAIs with different dosing intervals, including semi-annual formulations (PP6M).METHODS: Hazard ratios (HRs) for relapse were derived from an updated systematic review and incorporated into a Bayesian hierarchical model capturing the combined effects of route of administration and dosing frequency. Model outputs were used to populate a cost-consequence model developed from the UAE healthcare third-party payer perspective. Only direct medical costs were considered with hospitalization used as a proxy for relapse. Analyses were conducted over 1- and 5-year time horizons.RESULTS: Over the 1-year horizon, the total budget per patient decreased by approximately 8%, 26%, and 50% following switches from OAP to paliperidone palmitate 1-month, 3-month, and 6-month formulations respectively. This corresponded to an estimated saving of ~20,000 AED per patient per year with PP6M which was associated with the lowest predicted relapse rates. Although longer-acting LAIs were associated with higher pharmaceutical expenditure per injection, reductions in relapse-related hospitalizations generated budget saving that exceeded incremental drug costs. CONCLUSIONS: In the UAE context, transitioning patients with schizophrenia from OAPs to paliperidone LAIs, including PP6M, may improve disease control and lead to favorable economic outcomes. Improved adherence translates into clinically meaningful reductions in relapse, with overall cost savings driven by avoided hospitalizations, supporting broader adoption of LAI strategies.
- 2 March 2026
- Published by Seed SRL in Farmeconomia. Health economics and therapeutic pathways
- Vol. 27 (1) , 45-54
Open AccessClinical and Economic Benefits of Long-Acting Injectable Paliperidone in Schizophrenia: A UAE-Based Modeling Study
INTRODUCTION: Poor adherence to oral antipsychotic (OAP) therapy is a major driver of relapse in patients with schizophrenia, as only 50% or fewer patients are adherent to OAP during the first year, leading to suboptimal clinical outcomes and substantial healthcare costs. Long-acting injectable (LAI) antipsychotics enhance treatment continuity and sustained drug exposure, with real-world data showing improved effectiveness as dosing intervals lengthen due to better adherence. We evaluate the clinical and economic consequences, in the United Arab Emirates (UAE) healthcare setting, of switching patients with schizophrenia from OAPs to paliperidone LAIs with different dosing intervals, including semi-annual formulations (PP6M).METHODS: Hazard ratios (HRs) for relapse were derived from an updated systematic review and incorporated into a Bayesian hierarchical model capturing the combined effects of route of administration and dosing frequency. Model outputs were used to populate a cost-consequence model developed from the UAE healthcare third-party payer perspective. Only direct medical costs were considered with hospitalization used as a proxy for relapse. Analyses were conducted over 1- and 5-year time horizons.RESULTS: Over the 1-year horizon, the total budget per patient decreased by approximately 8%, 26%, and 50% following switches from OAP to paliperidone palmitate 1-month, 3-month, and 6-month formulations respectively. This corresponded to an estimated saving of ~20,000 AED per patient per year with PP6M which was associated with the lowest predicted relapse rates. Although longer-acting LAIs were associated with higher pharmaceutical expenditure per injection, reductions in relapse-related hospitalizations generated budget saving that exceeded incremental drug costs. CONCLUSIONS: In the UAE context, transitioning patients with schizophrenia from OAPs to paliperidone LAIs, including PP6M, may improve disease control and lead to favorable economic outcomes. Improved adherence translates into clinically meaningful reductions in relapse, with overall cost savings driven by avoided hospitalizations, supporting broader adoption of LAI strategies.